Disc Medicine said its treatment for a rare light-sensitivity disease cleared Phase 3 endpoints, setting up a renewed path for FDA engagement after a prior rejection. The company framed the result as a home-run outcome on all primary and key secondary endpoints. The update is a key reminder of how rare-disease development can hinge on regulator timing and trial execution details even when the underlying biology is unchanged. A successful Phase 3 also creates leverage for future negotiations on label language, safety requirements, and post-marketing evidence. For investors and clinicians following rare ophthalmic and dermatologic disorders, the company’s redemption plan could determine whether the drug returns to the market with broader confidence in both efficacy and tolerability.